Akari Therapeutics (AKTX) Total Non-Current Liabilities (2011 - 2026)
Akari Therapeutics (AKTX) posted quarterly Total Non-Current Liabilities of $19.5 million for Q1 2026, down 32.66% year-on-year from $28.9 million in Q1 2025, and up 0.82% on a QoQ basis from $19.3 million in Q4 2025.
Akari Therapeutics (AKTX) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has reported Total Non-Current Liabilities for 12 consecutive years, with $19.5 million the latest figure, recorded in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 32.66% year-over-year to $19.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.5 million (down 32.66% YoY) and the FY2025 annual result came in at $19.3 million, down 30.83% from the prior year.
- Total Non-Current Liabilities advanced to $19.5 million in Q1 2026 per AKTX's latest filing, from $19.3 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for AKTX reached as high as $28.9 million in Q1 2025 and fell as low as $2.6 million in Q3 2024.
- A 5-year average of $13.7 million and a median of $12.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Non-Current Liabilities surged 983.35% — and 2026, when it plunged 32.66%.
- Year by year, Total Non-Current Liabilities stood at $4.2 million in 2022, then slipped by 20.48% to $3.3 million in 2023, then surged by 739.09% to $28.0 million in 2024, then tumbled by 30.83% to $19.3 million in 2025, then advanced by 0.82% to $19.5 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $19.5 million, $19.3 million, and $22.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Akari Therapeutics | 86.55 Mn | 86.55 Mn | - | 19.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.49 Mn |
| Dec 31, 2025 | 19.33 Mn |
| Sep 30, 2025 | 22.59 Mn |
| Jun 30, 2025 | 25.18 Mn |
| Mar 31, 2025 | 28.95 Mn |
| Dec 31, 2024 | 27.95 Mn |
| Sep 30, 2024 | 2.63 Mn |
| Jun 30, 2024 | 4.98 Mn |
| Mar 31, 2024 | 2.67 Mn |
| Dec 31, 2023 | 3.33 Mn |
| Jun 30, 2023 | 3.53 Mn |
| Dec 31, 2022 | 4.19 Mn |
| Jun 30, 2018 | 213,204.00 |
| Dec 31, 2017 | 48,003.00 |
| Jun 30, 2017 | 58,036.00 |
| Dec 31, 2016 | 56,360.00 |
| Jun 30, 2016 | 55,131.00 |
| Mar 31, 2016 | 52,100.00 |
| Dec 31, 2015 | 49,069.00 |
| Sep 30, 2015 | 46,038.00 |